Avoro Capital Advisors 13F: Cuts LXEO Stake by $6.9M

Avoro Capital Advisors has significantly reduced its position in Lexeo Therapeutics, Inc. (NasdaqGM: LXEO). As of its latest SEC filing on May 15, 2026, Avoro cut its holdings by 1,425,000 shares, a 43% reduction, leaving it with 1,875,000 shares valued at approximately $8.19 million.

What Changed in Avoro Capital Advisors' Lexeo Therapeutics Position

Avoro Capital Advisors trimmed its stake in Lexeo Therapeutics from 3,300,000 shares to 1,875,000 shares, a decrease of 1,425,000 shares, or 43%. The firm’s reduced position is now valued at about $8.19 million. This move suggests a shift in Avoro's investment strategy regarding the biotechnology company.

Other Institutional Activity in Lexeo Therapeutics

Other funds have been active in Lexeo Therapeutics as well. Paradigm Biocapital Advisors LP increased its holdings by 1,420,936 shares, bringing its total to 6,184,134 shares valued at $35.5 million. BlackRock, Inc. added 203,308 shares, holding 5,110,871 shares worth roughly $29.3 million. Affinity Asset Advisors, LLC also grew its position by 1,850,211 shares, ending with 5,050,211 shares valued at $28.9 million. Meanwhile, Janus Henderson Group PLC reduced its stake by 533,206 shares, holding 4,976,429 shares valued at about $28.5 million.

Lexeo Therapeutics, Inc. Stock Up 14.5%

Shares of Lexeo Therapeutics traded around $4.37 recently. The company has a market capitalization of approximately $343.1 million. Although it is not currently profitable, it has a high beta of 1.389, indicating greater volatility compared to the market. The stock's 52-week range is between $3.60 and $10.99, with a 50-day moving average of $5.53 and a 200-day moving average of $7.14.

Insider Buying and Selling at Lexeo Therapeutics, Inc.

There has been notable insider activity at Lexeo Therapeutics. On May 18, 2026, COO Jose Manuel Otero sold 1,302 shares at an average price of $5.07, while CEO Richard Nolan Townsend sold 3,342 shares at $5.06. Earlier, on April 6, 2026, Townsend sold 55,000 shares under a planned sale at $5.69. However, both Townsend and Otero bought shares on March 13, 2026, at $2.64, with Townsend acquiring 2,623 shares and Otero buying 5,930 shares.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on Lexeo Therapeutics. On May 11, 2026, Chardan Capital maintained its 'buy' rating with a $17 target price. The consensus among analysts is also optimistic, with a mean target price of $20.60 based on 10 opinions.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines for hereditary and acquired diseases with unmet needs in the United States. Based in New York City, it is led by CEO R. Nolan Townsend. The company's pipeline includes gene therapy candidates for conditions such as Friedreich ataxia cardiomyopathy and APOE4-associated Alzheimer's disease.

Bottom Line

Avoro Capital Advisors' decision to cut its stake in Lexeo Therapeutics by 43% reflects a significant reevaluation of its investment in the company. Investors keep an eye on such movements to gauge the sentiment around a stock, though it's important to remember that 13F filings provide a backward-looking view. Lexeo's volatile stock and active insider transactions make it a company to watch in the dynamic biotech sector.